* Healthcare, energy stocks lift benchmark* Financials track Wall Street gains* New Zealand shares finish slightly lower (Updates to close)Jan 15 (Reuters) - Australian shares...
* Aussie benchmark briefly rises above 5,800 resistance level* Index down after 4 sessions of gains, posts weekly gain* Mining stocks and financials top drags* Energy stocks record...
* Financials and materials drive index higher* Continued buying may push ASX above resistance level- Analyst (Updates to close)By Rashmi AshokJan 10 (Reuters) - Australian shares...
Originally published by IG Markets Overnight bounce: As it currently stands, the Nasdaq – ground zero for much of the recent market correction – is leading the pack, up...
|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Moving Averages||Strong Sell||Strong Sell||Sell||Buy||Buy|
|Technical Indicators||Strong Sell||Strong Sell||Strong Sell||Strong Buy||Strong Buy|
|Summary||Strong Sell||Strong Sell||Strong Sell||Strong Buy||Strong Buy|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Inside Up||1M||Current|
|Three Black Crows||1M||2||Nov 18|
|Bullish doji Star||5H||2||Jan 21, 2019 13:00|
|Doji Star Bearish||1W||3||Dec 30, 2018|
|Charter Hall Group||7.660||7.670||7.560||+0.070||+0.92%||853.75K||22/01|
|Commonwealth Bank Australia||72.180||72.940||71.920||-0.870||-1.19%||2.14M||22/01|
|Washington H Soul Pattinson||26.550||26.890||26.420||+0.180||+0.68%||269.76K||22/01|
|National Australia Bank||24.590||24.890||24.475||-0.320||-1.28%||3.83M||22/01|
|ANZ Banking Group||25.810||26.150||25.700||-0.380||-1.45%||3.71M||22/01|
|BHP Billiton Ltd||32.770||33.135||32.760||-0.430||-1.30%||5.75M||22/01|
CSL Limited is a biotherapeutics company that develops and delivers biotherapies. The Company's principal activities are research, development, manufacture, marketing and distribution of biopharmaceutical and allied products. Its segments include CSL Behring, Seqirus and CSL Intellectual Property. The CSL Behring segment manufactures, markets and develops plasma therapies (plasma products and recombinants). The Seqirus segment manufactures and distributes non-plasma biotherapeutic products. Seqirus manufactures, sells and distributes a range of vaccines, antivenoms and other pharmaceutical products in Australia and New Zealand. It also manufactures and markets in vitro diagnostic products through Seqirus immunohematology. The CSL Intellectual Property segment is engaged in licensing of intellectual property generated by the Company to unrelated third parties. The Company has facilities in Australia, Germany, Switzerland, the United Kingdom and the United States.Read More
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.